Role of thermodynamic and kinetic parameters in gadolinium chelate stability
暂无分享,去创建一个
[1] T. Steger-Hartmann,et al. Impact of Renal Impairment on Long-Term Retention of Gadolinium in the Rodent Skin Following the Administration of Gadolinium-Based Contrast Agents , 2009, Investigative radiology.
[2] D. Løvhaug,et al. Effects of gadolinium contrast agents in naïve and nephrectomized rats: Relevance to nephrogenic systemic fibrosis , 2009, Acta radiologica.
[3] R. Swartz,et al. Effects of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents on Human Skin in Organ Culture and Human Skin Fibroblasts , 2009, Investigative radiology.
[4] T. Frenzel,et al. Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C , 2008, Investigative radiology.
[5] E. Lancelot,et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. , 2008, Toxicology.
[6] S. Morcos,et al. Extracellular gadolinium contrast agents: differences in stability. , 2008, European journal of radiology.
[7] C. Robic,et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review , 2008, BioMetals.
[8] T. Frenzel,et al. A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media , 2008, Investigative radiology.
[9] L. Skov,et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long‐term persistence in nephrogenic systemic fibrosis , 2007, The British journal of dermatology.
[10] P. Kuo. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. , 2008, Journal of the American College of Radiology : JACR.
[11] M. Perazella,et al. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. , 2008, Current drug safety.
[12] Walter Schmitt,et al. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development , 2008, Expert opinion on drug metabolism & toxicology.
[13] O. Döhr,et al. Preclinical Safety Evaluation of Gd-EOB-DTPA (Primovist) , 2007, Investigative radiology.
[14] Frank J Rybicki,et al. Biochemical safety profiles of gadolinium‐based extracellular contrast agents and nephrogenic systemic fibrosis , 2007, Journal of magnetic resonance imaging : JMRI.
[15] Charu Thakral,et al. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. , 2007, Contrast media & molecular imaging.
[16] H. Schmitt-Willich. Stability of linear and macrocyclic gadolinium based contrast agents. , 2007, The British journal of radiology.
[17] S. Morcos,et al. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? , 2007, The British journal of radiology.
[18] S. Cowper,et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.
[19] M. Port,et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.
[20] Lone Skov,et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.
[21] T. Steger-Hartmann,et al. Preclinical Safety Assessment of Vasovist (Gadofosveset trisodium), a New Magnetic Resonance Imaging Contrast Agent for Angiography , 2006, Investigative radiology.
[22] Sophie Laurent,et al. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. , 2006, Contrast media & molecular imaging.
[23] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[24] M. Tweedle,et al. Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy , 2006, Investigative radiology.
[25] V. Lorusso,et al. Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as 'sponges' of Gd3+ ions. , 2006, Contrast media & molecular imaging.
[26] M. D. de Broe,et al. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. , 2005, Kidney international.
[27] M. Port,et al. Complexing mechanism of the lanthanide cations Eu3+, Gd3+, and Tb3+ with 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (dota)-characterization of three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence , 2004, Chemistry.
[28] W. Gibby,et al. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission Spectroscopy , 2004, Investigative radiology.
[29] M. Wastie,et al. Gadolinium: named after Finland's most famous chemist. , 2004, The British journal of radiology.
[30] C. Corot,et al. Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation , 1998, Biometals.
[31] K. Kent,et al. Gadodiamide administration causes spurious hypocalcemia. , 2003, Radiology.
[32] E. Brücher. Kinetic Stabilities of Gadolinium(III) Chelates Used as MRI Contrast Agents , 2002 .
[33] G. Choppin,et al. Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging. , 2001, Inorganic chemistry.
[34] S. Laurent,et al. Stability of MRI Paramagnetic Contrast Media: A Proton Relaxometric Protocol for Transmetallation Assessment , 2001, Investigative radiology.
[35] E.,et al. Paramagnetic Metal Complexes as Water Proton Relaxation Agents for NMR Imaging : Theory and Design , 2001 .
[36] C. de Haën. Conception of the first magnetic resonance imaging contrast agents: a brief history. , 2001, Topics in magnetic resonance imaging : TMRI.
[37] E. Brücher,et al. The rates of the exchange reactions between [Gd(DTPA)]2- and the endogenous ions Cu2+ and Zn2+: a kinetic model for the prediction of the in vivo stability of [Gd(DTPA)]2-, used as a contrast agent in magnetic resonance imaging. , 2000, Chemistry.
[38] W. Heindel,et al. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. , 2000, Investigative radiology.
[39] A. Pałasz,et al. Toxicological and cytophysiological aspects of lanthanides action. , 2000, Acta biochimica Polonica.
[40] M. Port,et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. , 1999, Journal of pharmaceutical and biomedical analysis.
[41] R. Lauffer,et al. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.
[42] S. Swan,et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. , 1999, Investigative radiology.
[43] A. Bianchi,et al. Interaction of ATP with a Gd3+ complex employed as paramagnetic contrast agent in NMR imaging , 1999 .
[44] V. Lorusso,et al. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. , 1999, Academic radiology.
[45] H. Thomsen,et al. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.
[46] A. Reid,et al. Gadolinium Chloride Toxicity in the Rat , 1997, Toxicologic pathology.
[47] Krishan Kumar. Macrocyclic polyamino carboxylate complexes of Gd(III) as magnetic resonance imaging contrast agents , 1997 .
[48] W. Gibby,et al. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. , 1996, Investigative radiology.
[49] Éva Tóth,et al. Equilibrium and kinetic studies on complexes of 10-[2,3-dihydroxy-(1-hydroxymethyl)-propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate , 1996 .
[50] S. Hirano,et al. Exposure, metabolism, and toxicity of rare earths and related compounds. , 1996, Environmental health perspectives.
[51] M. Tweedle,et al. Synthesis, Stability, and Crystal Structure Studies of Some Ca2+, Cu2+, and Zn2+ Complexes of Macrocyclic Polyamino Carboxylates , 1995 .
[52] P. Wedeking,et al. Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats , 1995, Investigative radiology.
[53] M. Taupitz,et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. , 1995, Radiology.
[54] P. Anelli,et al. Novel Contrast Agents for Magnetic Resonance Imaging. Synthesis and Characterization of the Ligand BOPTA and Its Ln(III) Complexes (Ln = Gd, La, Lu). X-ray Structure of Disodium (TPS-9-145337286-C-S)-[4-Carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa- 5,8,11-triazatridecan-13-oato(5-)]gadolinate(2 , 1995 .
[55] J. Raymond,et al. Aluminum‐Induced DNA synthesis in osteobalsts: Mediation by a G‐protein coupled cation sensing mechanism , 1994, Journal of cellular biochemistry.
[56] I. Lázár,et al. Kinetics of Formation and Dissociation of Lanthanide(III)-DOTA Complexes , 1994 .
[57] M. Tweedle,et al. Equilibrium and Kinetic Studies of Lanthanide Complexes of Macrocyclic Polyamino Carboxylates , 1993 .
[58] T. J. Norman,et al. Synthesis of charged and uncharged complexes of gadolinium and yttrium with cyclic polyazaphosphinic acid ligands for in vivo applications , 1993 .
[59] T. Norman,et al. Hepato-biliary and renal excretion in mice of charged and neutral gadolinium complexes of cyclic tetra-aza-phosphinic and carboxylic acids. , 1993, Magnetic resonance imaging.
[60] M. Tweedle,et al. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. , 1992, Investigative radiology.
[61] Xiangyun Wang,et al. A kinetic investigation of the lanthanide DOTA chelates. Stability and rates of formation and of dissociation of a macrocyclic gadolinium(III) polyaza polycarboxylic MRI contrast agent , 1992 .
[62] S. Quay,et al. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. , 1991, Investigative radiology.
[63] J. Hagan,et al. Reaction of gadolinium chelates with endogenously available ions. , 1991, Magnetic resonance imaging.
[64] W. Cacheris,et al. The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.
[65] C. Evans. The Occurrence and Metabolism of Lanthanides , 1990 .
[66] M. Schaefer,et al. Gd‐DOTA, A Potential MRI Contrast Agent Current Status of Physicochemical Knowledge , 1988, Investigative radiology.
[67] P. Barthelemy,et al. Highly stable lanthanide macrocyclic complexes: in search of new contrast agents for NMR imaging. , 1988, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[68] D. Williams,et al. Chelating agents in medicine. , 1982, Journal of toxicology. Clinical toxicology.
[69] D. P. Mellor,et al. CHAPTER 1 – Historical Background and Fundamental Concepts , 1964 .